Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $35.80.

A number of research analysts have recently weighed in on VRDN shares. Wedbush reissued an "outperform" rating and issued a $42.00 price target on shares of Viridian Therapeutics in a research note on Monday, July 29th. The Goldman Sachs Group increased their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, September 12th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, September 10th. Needham & Company LLC increased their price target on Viridian Therapeutics from $30.00 to $38.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, September 19th.

Insiders Place Their Bets

In other news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Stephen F. Mahoney acquired 21,400 shares of Viridian Therapeutics stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 1,626,400 shares of company stock worth $30,616,312. Corporate insiders own 0.65% of the company's stock.

Hedge Funds Weigh In On Viridian Therapeutics

A number of large investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. boosted its stake in shares of Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock worth $87,000 after buying an additional 799 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company's stock worth $209,000 after buying an additional 1,058 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Viridian Therapeutics by 4.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company's stock valued at $505,000 after purchasing an additional 1,135 shares during the last quarter. Arizona State Retirement System lifted its stake in Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after purchasing an additional 1,688 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock valued at $156,000 after purchasing an additional 2,359 shares during the last quarter.

Viridian Therapeutics Trading Down 1.6 %

NASDAQ:VRDN traded down $0.41 during trading hours on Monday, hitting $24.57. 578,850 shares of the stock were exchanged, compared to its average volume of 1,122,468. The company's 50 day moving average is $19.52 and its two-hundred day moving average is $15.91. Viridian Therapeutics has a twelve month low of $10.93 and a twelve month high of $25.39. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.57 billion, a P/E ratio of -5.78 and a beta of 1.08.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.15). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. On average, sell-side analysts anticipate that Viridian Therapeutics will post -3.94 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.